Skip to content

EV / sales at other companies

Amgen logo
AmgenAMGN
6.6×+0.1×
Moderna logo
ModernaMRNA
8.8×+5.6×
Royalty Pharma logo
Royalty PharmaRPRX
11.9×+3.0×
ALN
Alnylam PharmaceuticalsALNY
9.9×-4.7×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
4.3×-0.4×
Incyte logo
IncyteINCY
2.9×+0.6×

Other financials

Income statement

See full
Revenue$2.5M-66.7%

Balance sheet

See full
Cash & equivalents$1.4B+1,411%
Total debt$107.4M+7.3%
Total equity$4.5B-3.4%
Total assets$5.7B+5.0%

Cash flow

See full
Operating cash flow-$163.8M+5.1%
CapEx$1.3M+55.5%
Free cash flow-$165.1M+4.8%

Valuation

See full
Market cap$22.61B+175%
Enterprise value$21.29B+157%
P/S2,736.9×+2,454×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio18.4×-15.1×

Where this comes from

Calculated from Roivant Sciences’s reported figures.

Based on the most recent quarter.

The official record: Roivant Sciences’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Roivant Sciences's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Roivant Sciences's EV / sales?
Roivant Sciences (ROIV) reported EV / sales of 2,241.3× in Q1 2026.
How has Roivant Sciences's EV / sales changed year-over-year?
Roivant Sciences's EV / sales increased by 803.7% year-over-year, from 248× to 2,241.3×.
What is the long-term trend for Roivant Sciences's EV / sales?
Over 4 years (2021 to 2025), Roivant Sciences's EV / sales has grown at a 82.9% compound annual growth rate (CAGR), from 377.7× to 4,222.4×.
What does EV / sales mean?
What the whole business costs relative to its annual sales.
How do you interpret EV / sales?
A fallback valuation gauge for pre-profit or cyclical firms. Like P/S, only comparable across similar-margin businesses, but it accounts for debt and cash unlike P/S.
How does EV / sales compare across companies?
Compare within a margin cohort; the debt-and-cash adjustment makes it cleaner than P/S for leveraged firms.